Tags · Sourcing
research use only
Material not approved for human use, sold for laboratory research.
Related in this group: certificate of analysis · batch & lot numbers · Janoshik Analytical · Medutest · PeptideMeter · VendorInvestigate · third-party testing · blind sampling · documentation quality · underdosing · mislabelling · customs
56 topics · page 2 of 2
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Payment mechanics and the recovery options that do not exist
Payment mechanics and the recovery options that do not exist Writing it up because I had to work it out twice and would rather nobody else did. I would like to talk about documentation quality as a signal,…
|
+80 | 89 | 24k | 9mo |
|
Research-use-only status: what it means legally and practically — does this still hold?
Asking directly, because I could not find a straight answer: Research-use-only status: what it means legally and practically — does this still hold? Session topic: SELECT ( N Engl J Med , 2023). Please read…
|
2 | 309 | 9mo | |
|
Compounds this community declines to help with, and why
Compounds this community declines to help with, and why — setting out what I have, and where I think it stops being reliable. Comparing LEADER ( N Engl J Med , 2016) with SCALE ( N Engl J Med , 2015) and…
|
+81 | 87 | 35k | 10mo |
|
Why catalogue breadth is not evidence of anything — what changed since
Asking directly, because I could not find a straight answer: Why catalogue breadth is not evidence of anything — what changed since Session topic: SURMOUNT-1 ( N Engl J Med , 2022). Please read it before…
|
+62 | 66 | 26k | 10mo |
|
Payment method and the leverage it gives you, ranked
Posting this under the heading it deserves: Payment method and the leverage it gives you, ranked Everything below is what sits behind that. Structured report rather than an opinion, following the format the…
|
+71 | 76 | 56k | 10mo |
|
Second pass at: Import rules for personal quantities, by jurisdiction, dated
Second pass at: Import rules for personal quantities, by jurisdiction, dated Writing it up because I had to work it out twice and would rather nobody else did. A logistics question, since the answers here are…
|
2 | 5k | 11mo | |
|
Revisiting: Why a compound being unapproved is not the same as being illegal to possess
On the subject in the title: Revisiting: Why a compound being unapproved is not the same as being illegal to possess Working notes rather than a conclusion. Structured report rather than an opinion, following…
|
+76 | 82 | 52k | 11mo |
|
Coming back to: When "no data" is the complete and final answer
When "no data" is the complete and final answer I have a specific reason for asking rather than idle curiosity, and the context is below. I have seen SURPASS-4 ( Lancet , 2021) cited in support of a claim I…
|
+77 | 82 | 12k | 11mo |
|
How to research a compound with no human data without deceiving yourself
Asking directly, because I could not find a straight answer: How to research a compound with no human data without deceiving yourself Session topic: STEP 2 ( Lancet , 2021). Please read it before posting; the…
|
+107 | 119 | 11k | 12mo |
|
Sequence verification for an obscure compound: how it is done
Sequence verification for an obscure compound: how it is done Writing it up because I had to work it out twice and would rather nobody else did. Comparing SUSTAIN 6 ( N Engl J Med , 2016) with SURMOUNT-1 ( N…
|
+104 | 114 | 10k | 12mo |
|
Payment mechanics and the recovery options that do not exist — what changed since
On the subject in the title: Payment mechanics and the recovery options that do not exist — what changed since Working notes rather than a conclusion. A logistics question, since the answers here are usually…
|
+14 | 18 | 17k | 13mo |
|
Reading a regulatory notice rather than an article about it — what changed since
Reading a regulatory notice rather than an article about it — what changed since — setting out what I have, and where I think it stops being reliable. A logistics question, since the answers here are usually…
|
+28 | 32 | 640 | 13mo |
|
Second pass at: How to research a compound with no human data without deceiving yourself
Second pass at: How to research a compound with no human data without deceiving yourself Writing it up because I had to work it out twice and would rather nobody else did. Comparing STEP 1 ( N Engl J Med ,…
|
+64 | 71 | 2.5k | 13mo |
|
Second pass at: A payment that went through twice: how it was resolved
On the subject in the title: Second pass at: A payment that went through twice: how it was resolved Working notes rather than a conclusion. A logistics question, since the answers here are usually better than…
|
2 | 1.1k | 14mo | |
|
Research-use-only labelling: what it means and what it does not — the long version
Posting this under the heading it deserves: Research-use-only labelling: what it means and what it does not — the long version Everything below is what sits behind that. I would like to talk about…
|
+150 | 158 | 55k | 14mo |
|
When "no data" is the complete and final answer
Asking directly, because I could not find a straight answer: When "no data" is the complete and final answer I have seen SURMOUNT-1 ( N Engl J Med , 2022) cited in support of a claim I do not think it…
|
+154 | 165 | 6.3k | 15mo |
|
What to keep a record of at the point of payment
What to keep a record of at the point of payment — that is the question, and I have not found it answered plainly anywhere I have looked. Structured report rather than an opinion, following the format the…
|
2 | 1.8k | 16mo | |
|
Research-use-only status: what it means legally and practically — a second dataset
Research-use-only status: what it means legally and practically — a second dataset — setting out what I have, and where I think it stops being reliable. Comparing FLOW ( N Engl J Med , 2024) with SURPASS-2 (…
|
+109 | 125 | 2k | 16mo |
|
How compounding permissions changed when supply normalised
Asking directly, because I could not find a straight answer: How compounding permissions changed when supply normalised Structured report rather than an opinion, following the format the maintainers asked…
|
+30 | 34 | 51k | 16mo |
|
Pharmaceutical compounding rules, summarised from primary sources
Pharmaceutical compounding rules, summarised from primary sources — setting out what I have, and where I think it stops being reliable. Structured report rather than an opinion, following the format the…
|
+135 | 163 | 46k | 17mo |
|
Follow-up: Why this community will not facilitate a group purchase
Why this community will not facilitate a group purchase I have a specific reason for asking rather than idle curiosity, and the context is below. A logistics question, since the answers here are usually…
|
2 | 19k | 18mo | |
|
About the Payments category
Payment mechanics, chargeback reality, and the recurring risks. No payment facilitation of any kind here. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is…
|
4 | 3.5k | 20mo | |
|
Coming back to: Research-use-only labelling: what it means and what it does not
Research-use-only labelling: what it means and what it does not — setting out what I have, and where I think it stops being reliable. Structured report rather than an opinion, following the format the…
|
+45 | 50 | 39k | 20mo |
|
Revisiting: Melanocortin agonists: mechanism and the documented adverse profile
Posting this under the heading it deserves: Revisiting: Melanocortin agonists: mechanism and the documented adverse profile Everything below is what sits behind that. Comparing SURMOUNT-4 ( JAMA , 2024) with…
|
+119 | 141 | 22k | 20mo |
|
Melanocortin agonists: mechanism and the documented adverse profile
Melanocortin agonists: mechanism and the documented adverse profile — setting out what I have, and where I think it stops being reliable. Comparing STEP 4 ( JAMA , 2021) with SURMOUNT-2 ( Lancet , 2023) and…
|
+7 | 11 | 5.5k | 20mo |
|
Naming conventions for research peptides and the confusion they cause — one year on
Naming conventions for research peptides and the confusion they cause — one year on — setting out what I have, and where I think it stops being reliable. I have seen SURMOUNT-2 ( Lancet , 2023) cited in…
|
+1 | 5 | 181 | 2y |